327 related articles for article (PubMed ID: 10996630)
21. [Vaccinal cell therapy in melanoma].
Quillien V; Lesimple T; Toujas L
Bull Cancer; 2003; 90(8-9):722-33. PubMed ID: 14609762
[TBL] [Abstract][Full Text] [Related]
22. Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T).
Javed A; Sato S; Sato T
Future Oncol; 2016 Mar; 12(6):751-62. PubMed ID: 26837440
[TBL] [Abstract][Full Text] [Related]
23. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
24. Perspective on allogeneic melanoma lysates in active specific immunotherapy.
Mitchell MS
Semin Oncol; 1998 Dec; 25(6):623-35. PubMed ID: 9865677
[TBL] [Abstract][Full Text] [Related]
25. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
26. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.
Perricone MA; Smith KA; Claussen KA; Plog MS; Hempel DM; Roberts BL; St George JA; Kaplan JM
J Immunother; 2004; 27(4):273-81. PubMed ID: 15235388
[TBL] [Abstract][Full Text] [Related]
27. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells in melanoma immunotherapy.
Faries MB; Czerniecki BJ
Curr Treat Options Oncol; 2005 May; 6(3):175-84. PubMed ID: 15869729
[TBL] [Abstract][Full Text] [Related]
29. DC therapy for metastatic melanoma.
Ingram SB; O'Rourke MG
Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
[No Abstract] [Full Text] [Related]
30. Characterization of polyvalent allogeneic vaccines.
Van Epps D
Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
[TBL] [Abstract][Full Text] [Related]
31. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
33. Advances in the non-surgical treatment of melanoma.
Hersey P
Expert Opin Investig Drugs; 2002 Jan; 11(1):75-85. PubMed ID: 11772323
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
35. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
36. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
37. Melanoma vaccines.
Minev BR
Semin Oncol; 2002 Oct; 29(5):479-93. PubMed ID: 12407513
[TBL] [Abstract][Full Text] [Related]
38. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma.
Yang HG; Hu BL; Xiao L; Wang P
Cancer Gene Ther; 2011 May; 18(5):370-80. PubMed ID: 21372855
[TBL] [Abstract][Full Text] [Related]
40. Autologous versus allogeneic cell-based vaccines?
Parmiani G; Pilla L; Maccalli C; Russo V
Cancer J; 2011; 17(5):331-6. PubMed ID: 21952283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
